- All Categories
- E-Services
Nahdi GlobalFlash Sales
Promo Flyer
Nahdicare Health center
Milk Promo Flyer
Aprizla 30 mg Tablets
Apremilast 30 mg
Film-coated tablets – Oral use
Aprizla is an anti-inflammatory medicine belonging to a group called phosphodiesterase 4 (PDE4) inhibitors. It is used in adults to treat:
Active psoriatic arthritis
(when other treatments such as DMARDs are not suitable or have not worked)
Moderate to severe chronic plaque psoriasis
(when treatments like phototherapy or systemic therapy are unsuitable or ineffective)
Aprizla reduces inflammation by lowering the activity of the enzyme phosphodiesterase 4, which plays a role in inflammatory processes.
This helps:
Reduce joint pain and swelling in psoriatic arthritis
Improve skin plaques and symptoms of psoriasis
Enhance overall quality of life
Treatment starts with a gradual dose increase over the first 6 days
Recommended maintenance dose:
30 mg twice daily (morning and evening, about 12 hours apart)
Total daily dose: 60 mg
Tablets should be swallowed whole with water
Can be taken with or without food
For severe kidney impairment:
Recommended dose is 30 mg once daily (morning only)
Do not use Aprizla if:
You are allergic to apremilast or any of the ingredients
You are pregnant or planning pregnancy
Consult your doctor if you:
Have depression or mood changes
Experience unexplained weight loss
Have severe kidney problems
Develop severe diarrhea, nausea, or vomiting
Tell your doctor if you take:
Rifampicin
Carbamazepine, phenytoin, phenobarbital
St John’s Wort
Very common:
Diarrhea
Nausea
Headache
Upper respiratory infections
Common:
Vomiting
Stomach pain
Loss of appetite
Insomnia
Depression
Uncommon but serious:
Mood changes or suicidal thoughts
Severe allergic reactions
Unintended weight loss
Seek medical help immediately if severe side effects occur.
Store below 30°C
Keep out of reach of children
Do not use after expiry date
Do not use if packaging is damaged
Each tablet contains Apremilast 30 mg
Product Details:
Aprizla 30 mg Tablets
Apremilast 30 mg
Film-coated tablets – Oral use
Aprizla is an anti-inflammatory medicine belonging to a group called phosphodiesterase 4 (PDE4) inhibitors. It is used in adults to treat:
Active psoriatic arthritis
(when other treatments such as DMARDs are not suitable or have not worked)
Moderate to severe chronic plaque psoriasis
(when treatments like phototherapy or systemic therapy are unsuitable or ineffective)
Aprizla reduces inflammation by lowering the activity of the enzyme phosphodiesterase 4, which plays a role in inflammatory processes.
This helps:
Reduce joint pain and swelling in psoriatic arthritis
Improve skin plaques and symptoms of psoriasis
Enhance overall quality of life
Treatment starts with a gradual dose increase over the first 6 days
Recommended maintenance dose:
30 mg twice daily (morning and evening, about 12 hours apart)
Total daily dose: 60 mg
Tablets should be swallowed whole with water
Can be taken with or without food
For severe kidney impairment:
Recommended dose is 30 mg once daily (morning only)
Do not use Aprizla if:
You are allergic to apremilast or any of the ingredients
You are pregnant or planning pregnancy
Consult your doctor if you:
Have depression or mood changes
Experience unexplained weight loss
Have severe kidney problems
Develop severe diarrhea, nausea, or vomiting
Tell your doctor if you take:
Rifampicin
Carbamazepine, phenytoin, phenobarbital
St John’s Wort
Very common:
Diarrhea
Nausea
Headache
Upper respiratory infections
Common:
Vomiting
Stomach pain
Loss of appetite
Insomnia
Depression
Uncommon but serious:
Mood changes or suicidal thoughts
Severe allergic reactions
Unintended weight loss
Seek medical help immediately if severe side effects occur.
Store below 30°C
Keep out of reach of children
Do not use after expiry date
Do not use if packaging is damaged
Each tablet contains Apremilast 30 mg
Product Details: